Harras Pharma
Harras Pharma HOME Company Export Contact
Service Telephone: +49 89 747 367 0
Deutsch
Espanol

Harras Pharma
Harras Pharma HOME Company Export Contact
Service Telephone: +49 89 747 367 0
Deutsch
Espanol

Sensicutan® Cream

For Neurodermatitis

 

 

 

  

  • steroid-free, long-term and low risk therapeutic agent
  • potent anti-inflammatory agent
  • fast relief of itching (for acute and chronic eczema)
  • excellent skin tolerance
  • pleasant cosmetic tolerance

 

  Brief Information     Pharmacological Profile
  Mechanism of action 
  Literature

 

 

Brief Information

Composition:

levomenol (alpha-bisabolol)

0.30 g

sodium heparin

20 000 IU

emulsion cream base

ad 100.00 g


 

Drug Presentation and Package Sizes:

30 g Sensicutan® Cream
80 g Sensicutan® Cream

 

Indications:

Acute and chronic eczema, dermatitis (e.g. atopic dermatitis / neurodermatitis), inflammatory
allergic skin diseases, prurigo (itching).

 

Mode of Administration and Dosage Directions:

For external use: If not otherwise directed, apply to the affected skin areas 2-3 times daily; also
suited for cream / occlusive dressings.

 

 

Contraindications:

Hypersensitivity to heparin or any other ingredient contained in Sensicutan® Cream.

 

Side Effects:

Allergic skin reactions may occur in very rare cases of patients with extremely sensitive skin. In general, these skin symptoms disappear quickly. A physician should be consulted if a specific allergic reaction occurs.

 

Drug Interaction:

No drug interactions are known.

 

Sensicutan® Cream
Stops itching, heals eczematous skin


Pharmacological Profile

Development of eczema: complex and multifaceted

The process involved in the development
and spread of eczema is complex and multifaceted and is frequently of diverse pathogenesis. Therefore, in order to treat eczematous skin symptoms with a specific and promising therapy, it is important that the treatment contain various dermatologically effective substances.

Stereoid-free local therapy

Indications: Eczema, neurodermatitis, prurigo

Sensicutan® Cream is a steroid-free local therapeutic agent for the treatment of skin disorders which fall under the general disease form eczema and which are frequently accompanied by itching, such as

  • acute and chronic eczema
  • dermatitis (e.g. atopic dermatitis / neurodermatitis)
  • allergic skin symptoms

Highly-developed emulsion system

The emulsion system of Sensicutan® Cream is highly-developed in terms of its galenic and cosmetic properties and, in its moisturizing cream base, contains the two active substances

  • levomenol (alpha-bisabolol) and
  • sodium heparin.

 

 

Balanced combination

The well-matched and balanced combination provides for a rapid onset of action characterized by

  • potent anti-inflammatory action and
  •  fast relief of itching.

Typical eczema symptoms

Typical eczematous skin symptoms such as

  • burning
  • redness
  • swelling
  • peeling / scaling

recede quickly with Sensicutan® therapy which is generally well tolerated by the skin.

Good skin tolercance / Non-irritating to skin

Especially suited for sensitive skin

Sensicutan® Cream is also suited for sensitive skin areas as well as being particularly suited for the treatment of neurodermatitis which is seen more and more frequently in children and infants.

Long-term therapeutic agent

Sensicutan® Cream can be employed for long-term therapy of very persistent allergic skin diseases and eczema equally well in patients with dry, normal and greasy / oily skin.

Sensicutan® Cream soothes and heals skin irritated and damaged by scratching.

 

 

 

Mechanism of action

The cutaneous anti-inflammatory agent
The mode of action involving the specific anti-inflammatory effect is of primary importance for the treatment of eczema and allergic skin diseases.

Good skin penetration

Specific antiphlogistic efficacy
Both active substances contained in SENSICUTAN® Cream - namely levomenol (alpha-bisabolol) and sodium heparin - penetrate the skin well. It is here that they exert their specific antiphlogistic action and inhibit inflammation mediators. As a result, reddening of the skin (erythema) and burning - two typical symptoms of eczema - subside.

  Fast relief of itching

Binding of Histamine
Itching, observed as a frequent, unpleasant secondary symptom of eczema, is suppressed
by the marked efficacy of sodium heparin. This natural substance binds histamine which is
known to be released in greater quantities in eczema and which is the main cause of the sometimes unbearable itching experienced
in this condition.

Besides this, heparin also has an inhibitory
effect on various lysosomal enzymes - an effect common also to other anti-inflammatory agents.
At the same time, through the binding of histamine, heparin relieves itching / exerts an anti-allergic effect.

Restores healthy skin via metabolic
Via metabolic activation, the combination of sodium heparin and levomenol (alpha-bisabolol), contained in Sensicutan® Cream, restores the epithelium of the skin, previously damaged by the eczema.
 

 

Literature:

P. ARENBERGER et al.:
Clinical double-blind four-arm study: Additive cutaneous efficacy of Sensicutan in the treatment of neurodermatitis testing 278 patients (2011).

P. ARENBERGER et al.:
Clinicial double-blind study:
Evaluation of the efficacy and safety of Sensicutan® with Dermatitis atopica and eczema caused by allergy - 104 patients - in comparison with placebo (2005)

SELZLE, D.:
Expert report on the application of Sensicutan® with Dermatitis atopica and chronic eczemas (1993)

TRONNIER, RÜPING:
Expert report on a observational study in a dermatological practice regarding efficacy and tolerability.
Institute for Experimental Dermatology, University Witten-Herdecke (1991)

TRONNIER:
Specialist’s dermatogical expert reporton an epicutaneous test
Institute for Experimental Dermatology, University Witten-Herdecke (1990)

TRONNIER, HEINRICH:
Expert Opinion: Application test with Sensicutan Cream.
Institute for Experimental Dermatology, Witten-Herdecke (1990)

B. HAHN, J. HÖLZL:
Arzneim.-Forsch. 37, (1), Nr. 6, (1987), 716-720

J.RING, H. FRÖHLICH:
"Wirkstoffe in der dermatologischen Therapie", Springer-Verlag, Berlin - Heidelberg - New York - Tokyo (1985), 190-191

H. WAGNER:
"Pharmazeutische Biologie" 3. Aufl., Gustav-Fischer-Verlag, Stuttgart - New York, (1985), 75

  P. FRITSCH:
"Dermatologie", Springer-Verlag, Berlin - Heidelberg - New York (1983), 94-95

T.K. YANG, H.M. JENKIN:
Proceedings of the society for experimental biology and medicine 159, 88-93 (1978)

H.J. SALIBA, Jr.:
Aerospace Medicine, Nov. 1970, 1302-1306

D.A. DOLOWITZ, T.F. DOUGHERTY:
Annals of Allergy, Vol. 23, July 1965, 309-313

T.F. DOUGHERTY, D.A. DOLOWITZ:
Americ. J. of. Cardiology, 14, July 1964, 18-24
J.-L. PARROT, C. LABORDE:
Societe de Biologie, Seance du 7 Juillet 1951, 1047-1051

S.B. STOKER:
British Medical Journal 360, Aug. 11, (1951)
 
 
© HARRAS PHARMA CURARINA Arzneimittel GmbH • 2019